Description
⋅ RARE: Ultragenyx Pharmaceutical Inc.
2020-01-09 16:01:10
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency